Chemoradiation for unresectable gall bladder cancer: time to review historic nihilism?
OBJECTIVE
Treatment of unresectable locally advanced gallbladder cancers (LAGBC) usually consists of various palliative strategies which provide only a modest survival benefit. Here, we present a series of three patients of LAGBC-treated consecutively at our center with preoperative chemoradiation using tomotherapy and concurrent gemcitabine.


METHODS
All three cases were reported to be adenocarcinoma by biopsy or fine-needle aspiration cytology. All the patients underwent positron emission tomography with computerized tomography scan to rule out distant metastasis and also to map the extent of disease for radiotherapy planning. Preoperative chemoradiation consisted of gemcitabine at 300 mg/m(2) weekly and tomotherapy with daily image guidance with MVCT over 5 weeks to a dose of 57 Gy in 25 fractions to the gross tumor and 45 Gy in 25 fractions to the clinical target volume to cover the areas of microscopic spread.


RESULTS
Complete metabolic and radiologic response was observed for 2 patients and partial response for 1 patient. Two patients underwent complete surgical excision of which 1 patient had complete pathological response and 1 patient had small residual tumor at the primary and no nodal metastasis. The third patient could not undergo surgery due to medical reasons.


CONCLUSIONS
The clinical outcome for unresectable LAGBC with preoperative chemoradiation in terms of feasibility, safety, and survival is encouraging. This treatment strategy has a curative potential for the otherwise fatal disease.
Engineer
Reena
R
Tata Memorial Centre, Mumbai, India. reena_engineer@rediffmail.com
Wadasadawala
Tabassum
T
Mehta
Shaesta
S
Mahantshetty
Umesh
U
Purandare
Nilendu
N
Rangarajan
Venkatesh
V
Kishore Shrivastava
Shyam
S
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D017322:Clinical Trials, Phase II as Topic; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005706:Gallbladder Neoplasms / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine
Ann Surg. 1996 Nov;224(5):639-46
8916879
CA Cancer J Clin. 2001 Nov-Dec;51(6):349-64
11760569
Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):969-74
12095564
Rev Med Chil. 2004 Jan;132(1):51-7
15379053
Am J Clin Oncol. 2003 Apr;26(2):174-7
12714891
J Hepatobiliary Pancreat Surg. 2008;15(6):655-8
18987939
Int J Radiat Oncol Biol Phys. 1988 Sep;15(3):735-44
2843489
Anticancer Res. 2009 May;29(5):1783-6
19443404
Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):913-9
10705013
J Clin Oncol. 1997 Jun;15(6):2403-13
9196156
World J Gastroenterol. 2003 Nov;9(11):2561-4
14606097
Semin Liver Dis. 1990 May;10(2):131-41
2162565
Int Arch Med. 2009 Mar 27;2(1):7
19327152
Ann Oncol. 2009 Jan;20(1):146-59
18667395
Br J Cancer. 2008 Sep 16;99(6):862-7
19238628
J Gastrointest Surg. 2004 Jan;8(1):90-7
14746840
Eur J Surg Oncol. 2008 Jul;34(7):756-64
18191528
Radiother Oncol. 2009 Aug;92(2):249-54
19324442
Surg Gynecol Obstet. 1978 Dec;147(6):929-42
362580
Radiother Oncol. 2006 Oct;81(1):65-72
16971012
J Am Coll Surg. 2008 Jan;206(1):57-65
18155569